Floatz logo

342 assets in Glioblastoma

Therapeutic assets addressing Glioblastoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
[177lu]lu-xt771
Glioblastoma
Beijing Tiantan HospitalEarly P1C (39)
Bemcentinib
Glioblastoma
BerGenBio ASAP1C (39)
Bms-986504
Glioblastoma
Nader SanaiEarly P1C (39)
Quisinostat
Glioblastoma
Nader SanaiEarly P1C (39)
Recombinant L-Ifn Adenovirus
Glioblastoma
Binhai Hospital of Fujian Medical UniversityEarly P1C (39)
Bgb-58067
Glioblastoma
Nader SanaiEarly P1C (38)
Dsp-0390
Glioblastoma
Sumitomo Pharma America, Inc.Early P1C (38)
Fimepinostat
Glioblastoma
Sabine Mueller, MD, PhDEarly P1C (38)
Nrg-103
Glioblastoma
Zhongnan HospitalEarly P1C (38)
Progesterone
Glioblastoma
Emory UniversityEarly P1C (38)
Risvutatug Rezetecan
Glioblastoma
Nader SanaiEarly P1C (38)
Targeted Epidermal Growth Factor Receptor Variant Iii Autochimeric Antigen Receptor T Cell
Glioblastoma
Beijing Tsinghua Chang Gung HospitalEarly P1C (38)
Ysch-01
Glioblastoma
Huashan HospitalEarly P1C (38)
131i-ipa
Glioblastoma
Telix Pharmaceuticals (Innovations) Pty LimitedP1C (37)
²¹²pb-dotam-grpr1
Glioblastoma
Orano Med Theranostics, SASP1C (37)
Abbv-637
Glioblastoma
Memorial Sloan Kettering Cancer CenterP1C (37)
Abexinostat
Glioblastoma
University of NebraskaP1C (37)
Ad5-yCD
Glioblastoma
Henry Ford Health SystemP1C (37)
ad5-ycd/muttksr39rep-adp adenovirus
Glioblastoma
Henry Ford Health SystemP1C (37)
b7-h3-car t cells
Glioblastoma
St. Jude Children's Research HospitalP1C (37)
b7-h3-targeting car-t cells
Glioblastoma
Beijing Tiantan HospitalP1C (37)
Belzutifan
Glioblastoma
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)P1C (37)
c134
Glioblastoma
James Markert, MDP1C (37)
c5252
Glioblastoma
ImmVira Pharma Co. LtdP1C (37)
Cart-Egfr-Il13Ra2 T Cells
Glioblastoma
University of PennsylvaniaP1C (37)
Carv3-Team-E T Cells
Glioblastoma
Marcela V. Maus, M.D.,Ph.D.P1C (37)
CD19t
Glioblastoma
City of Hope Medical CenterP1C (37)
Cetuximab-Irdye800
Glioblastoma
University Medical Center GroningenP1C (37)
Cynk-001
Glioblastoma
Celularity IncorporatedP1/2C (37)
Dual-Target Car-Nk Cells
Glioblastoma
Beijing BiotechP1C (37)
Eflornithine
Glioblastoma
Orbus Therapeutics, Inc.P1C (37)
Eras-801
Glioblastoma
Jonsson Comprehensive Cancer CenterP1C (37)
E-Sync T Cells
Glioblastoma
Hideho Okada, MD, PhDP1C (37)
Evolocumab
Glioblastoma
Duke UniversityEarly P1C (37)
Ezabenlimab
Glioblastoma
Johann Wolfgang Goethe University HospitalP1C (37)
ft536
Glioblastoma
Masonic Cancer Center, University of MinnesotaP1C (37)
Glix1
Glioblastoma
Tetragon Biosciences LtdP1C (37)
her2bbζ/cd19t+ t cells
Glioblastoma
City of Hope Medical CenterP1C (37)
HER2(EQ)BBzeta
Glioblastoma
City of Hope Medical CenterP1C (37)
Ibrutinib
Glioblastoma
Theodore S. JohnsonP1C (37)
il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells
Glioblastoma
City of Hope Medical CenterP1C (37)
Linrodostat
Glioblastoma
Northwestern UniversityP1C (37)
Maprotiline
Glioblastoma
University of RochesterP1C (37)
Mirzotamab Clezutoclax
Glioblastoma
Memorial Sloan Kettering Cancer CenterP1C (37)
mt-201-gbm monocyte vaccine
Glioblastoma
Michael GunnP1C (37)
NK-92
Glioblastoma
Johann Wolfgang Goethe University HospitalP1C (37)
nk-92/5.28.z
Glioblastoma
Johann Wolfgang Goethe University HospitalP1C (37)
Okn 007
Glioblastoma
University of OklahomaP1C (37)
Olanzapine
Glioblastoma
National Cancer Institute (NCI)P1C (37)
Onc 206
Glioblastoma
Sabine Mueller, MD, PhDP1C (37)
Showing 251 to 300 of 342 assets
PreviousPage 6 of 7Next